10am – 12pm Unlocking the Power of Cord Blood as a Platform for Scalable Manufacturing of Universal Cell Therapy Products

Time: 12:15 am
day: Pre-Conference: Manufacturing & CMC


As differences in CAR-T product potency and persistency have, to date, shown correlation with composition of donor starting material and T cell identity, it is important to understand the phenotypes and functional characteristics that impact in vivo potency. This session will discuss attributes of T cell stemness enriched in the placenta versus adult peripheral blood T cells which translate to in vitro and in vivo functional benefits in a manufactured CAR-T product. Join this session to explore the implications of T cell subsets and further differentiation in CAR-T manufacture, functional characterization of cytotoxicity and cytokine effector responses, immune checkpoints, and considerations for characterizing drug product identity